Loading…
Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma
BackgroundSquamous cell carcinoma (SCC) of the bladder is common in many regions around the world. Prognosis is very poor, as most cases are diagnosed at an advanced stage due to a lack of affordable and valid screening markers for this type of cancer. The diagnostic accuracy of urinary nuclear matr...
Saved in:
Published in: | Current urology 2022-09, Vol.16 (3), p.154-159 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c400t-5d2f1221575612d16653ffda0649c1d0509f2485ba156637648a89e4a46876d83 |
container_end_page | 159 |
container_issue | 3 |
container_start_page | 154 |
container_title | Current urology |
container_volume | 16 |
creator | Al-Delaimy, Wael K. Awadalla, Amira El-Assmy, Ahmed Abol-Enein, Hassan Shokeir, Ahmed |
description | BackgroundSquamous cell carcinoma (SCC) of the bladder is common in many regions around the world. Prognosis is very poor, as most cases are diagnosed at an advanced stage due to a lack of affordable and valid screening markers for this type of cancer. The diagnostic accuracy of urinary nuclear matrix protein-22 (NMP22), telomerase activity, and CD44 were evaluated in urine samples of patients with bladder SCC. Materials and methodsWe conducted a case-control study comprised of 60 consecutive newly diagnosed bladder SCC patients diagnosed by cystoscopy and histopathological examination, and controls were 60 outpatients with benign urologic conditions and healthy clinic visitors. Urine samples collected from each subject underwent testing for NMP22, telomerase activity, and CD44. Descriptive and correlational statistical analysis of cases and controls were carried out and receiver operating characteristic curve analysis was used to determine optimal cut-off points for the three assays. ResultsArea under the curve was calculated at 0.96, 0.93, and 0.62 for NMP22, telomerase, and CD44, respectively. Urine levels of NMP22 and telomerase activity were significantly higher in the SCC group compared to controls (p < 0.001). Urine CD44 levels were not significantly higher in the SCC group compared to controls (p = 0.111). The overall sensitivity of NMP22, telomerase, and CD44 was 96.7%, 87%, and 45%, respectively, while the specificity was 85%, 88.6%, and 86.7%, respectively. ConclusionsUrinary telomerase activity, followed by NMP22 urine levels, showed high diagnostic yield and could hold potential promise as urinary biomarkers for the diagnosis of bladder SCC. |
doi_str_mv | 10.1097/CU9.0000000000000098 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_eb269b0877134b5ea9d48329cf831ad1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_eb269b0877134b5ea9d48329cf831ad1</doaj_id><sourcerecordid>2723156186</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-5d2f1221575612d16653ffda0649c1d0509f2485ba156637648a89e4a46876d83</originalsourceid><addsrcrecordid>eNpdkclOHDEQhltRIoUQ3iAHHzkwE-_LBSnqQIJElgOcrWovxKi7PdjdkXh7TAYhTXwpy676qv76u-4TwVuCjfrc35otPjhGv-mOiJRko6RQb1_v3LzvPtR6j7HklLGjLvV52kFJNc8oR7SWNEN5REsY8xQK1HCG-q-cnyGYPfr54zelCGqFx4piLsiHJbgl7WuHEbwPBdWHFaa8VuTCOCIHxaU5T_CxexdhrOHkJR53t5cXN_33zfWvb1f9l-uN4xgvG-FpJJQSoYQk1Le5BYvRQxvYOOKxwCZSrsUAREjJmiQN2gQOXGolvWbH3dWe6zPc211JUxNkMyT77yGXOwtlSW4MNgxUmgFrpQjjgwhgPNeMGhc1I-BJY53vWbt1mIJ3YV4KjAfQw585_bF3-a81gipDTAOcvgBKflhDXeyU6vNeYA5tRZYqypoOomVL5ftUV3KtJcTXNgTbZ5tts9n-bzN7AodgmbQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2723156186</pqid></control><display><type>article</type><title>Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma</title><source>Open Access: PubMed Central</source><source>HEAL-Link subscriptions: Lippincott Williams & Wilkins</source><creator>Al-Delaimy, Wael K. ; Awadalla, Amira ; El-Assmy, Ahmed ; Abol-Enein, Hassan ; Shokeir, Ahmed</creator><creatorcontrib>Al-Delaimy, Wael K. ; Awadalla, Amira ; El-Assmy, Ahmed ; Abol-Enein, Hassan ; Shokeir, Ahmed</creatorcontrib><description>BackgroundSquamous cell carcinoma (SCC) of the bladder is common in many regions around the world. Prognosis is very poor, as most cases are diagnosed at an advanced stage due to a lack of affordable and valid screening markers for this type of cancer. The diagnostic accuracy of urinary nuclear matrix protein-22 (NMP22), telomerase activity, and CD44 were evaluated in urine samples of patients with bladder SCC. Materials and methodsWe conducted a case-control study comprised of 60 consecutive newly diagnosed bladder SCC patients diagnosed by cystoscopy and histopathological examination, and controls were 60 outpatients with benign urologic conditions and healthy clinic visitors. Urine samples collected from each subject underwent testing for NMP22, telomerase activity, and CD44. Descriptive and correlational statistical analysis of cases and controls were carried out and receiver operating characteristic curve analysis was used to determine optimal cut-off points for the three assays. ResultsArea under the curve was calculated at 0.96, 0.93, and 0.62 for NMP22, telomerase, and CD44, respectively. Urine levels of NMP22 and telomerase activity were significantly higher in the SCC group compared to controls (p < 0.001). Urine CD44 levels were not significantly higher in the SCC group compared to controls (p = 0.111). The overall sensitivity of NMP22, telomerase, and CD44 was 96.7%, 87%, and 45%, respectively, while the specificity was 85%, 88.6%, and 86.7%, respectively. ConclusionsUrinary telomerase activity, followed by NMP22 urine levels, showed high diagnostic yield and could hold potential promise as urinary biomarkers for the diagnosis of bladder SCC.</description><identifier>ISSN: 1661-7649</identifier><identifier>EISSN: 1661-7657</identifier><identifier>DOI: 10.1097/CU9.0000000000000098</identifier><language>eng</language><publisher>Lippincott Williams & Wilkins</publisher><subject>Special Topic: Advances in bladder cancer therapy: Original</subject><ispartof>Current urology, 2022-09, Vol.16 (3), p.154-159</ispartof><rights>Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. 2022 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c400t-5d2f1221575612d16653ffda0649c1d0509f2485ba156637648a89e4a46876d83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527919/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527919/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids></links><search><creatorcontrib>Al-Delaimy, Wael K.</creatorcontrib><creatorcontrib>Awadalla, Amira</creatorcontrib><creatorcontrib>El-Assmy, Ahmed</creatorcontrib><creatorcontrib>Abol-Enein, Hassan</creatorcontrib><creatorcontrib>Shokeir, Ahmed</creatorcontrib><title>Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma</title><title>Current urology</title><description>BackgroundSquamous cell carcinoma (SCC) of the bladder is common in many regions around the world. Prognosis is very poor, as most cases are diagnosed at an advanced stage due to a lack of affordable and valid screening markers for this type of cancer. The diagnostic accuracy of urinary nuclear matrix protein-22 (NMP22), telomerase activity, and CD44 were evaluated in urine samples of patients with bladder SCC. Materials and methodsWe conducted a case-control study comprised of 60 consecutive newly diagnosed bladder SCC patients diagnosed by cystoscopy and histopathological examination, and controls were 60 outpatients with benign urologic conditions and healthy clinic visitors. Urine samples collected from each subject underwent testing for NMP22, telomerase activity, and CD44. Descriptive and correlational statistical analysis of cases and controls were carried out and receiver operating characteristic curve analysis was used to determine optimal cut-off points for the three assays. ResultsArea under the curve was calculated at 0.96, 0.93, and 0.62 for NMP22, telomerase, and CD44, respectively. Urine levels of NMP22 and telomerase activity were significantly higher in the SCC group compared to controls (p < 0.001). Urine CD44 levels were not significantly higher in the SCC group compared to controls (p = 0.111). The overall sensitivity of NMP22, telomerase, and CD44 was 96.7%, 87%, and 45%, respectively, while the specificity was 85%, 88.6%, and 86.7%, respectively. ConclusionsUrinary telomerase activity, followed by NMP22 urine levels, showed high diagnostic yield and could hold potential promise as urinary biomarkers for the diagnosis of bladder SCC.</description><subject>Special Topic: Advances in bladder cancer therapy: Original</subject><issn>1661-7649</issn><issn>1661-7657</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpdkclOHDEQhltRIoUQ3iAHHzkwE-_LBSnqQIJElgOcrWovxKi7PdjdkXh7TAYhTXwpy676qv76u-4TwVuCjfrc35otPjhGv-mOiJRko6RQb1_v3LzvPtR6j7HklLGjLvV52kFJNc8oR7SWNEN5REsY8xQK1HCG-q-cnyGYPfr54zelCGqFx4piLsiHJbgl7WuHEbwPBdWHFaa8VuTCOCIHxaU5T_CxexdhrOHkJR53t5cXN_33zfWvb1f9l-uN4xgvG-FpJJQSoYQk1Le5BYvRQxvYOOKxwCZSrsUAREjJmiQN2gQOXGolvWbH3dWe6zPc211JUxNkMyT77yGXOwtlSW4MNgxUmgFrpQjjgwhgPNeMGhc1I-BJY53vWbt1mIJ3YV4KjAfQw585_bF3-a81gipDTAOcvgBKflhDXeyU6vNeYA5tRZYqypoOomVL5ftUV3KtJcTXNgTbZ5tts9n-bzN7AodgmbQ</recordid><startdate>20220901</startdate><enddate>20220901</enddate><creator>Al-Delaimy, Wael K.</creator><creator>Awadalla, Amira</creator><creator>El-Assmy, Ahmed</creator><creator>Abol-Enein, Hassan</creator><creator>Shokeir, Ahmed</creator><general>Lippincott Williams & Wilkins</general><general>Wolters Kluwer Health</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220901</creationdate><title>Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma</title><author>Al-Delaimy, Wael K. ; Awadalla, Amira ; El-Assmy, Ahmed ; Abol-Enein, Hassan ; Shokeir, Ahmed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-5d2f1221575612d16653ffda0649c1d0509f2485ba156637648a89e4a46876d83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Special Topic: Advances in bladder cancer therapy: Original</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Delaimy, Wael K.</creatorcontrib><creatorcontrib>Awadalla, Amira</creatorcontrib><creatorcontrib>El-Assmy, Ahmed</creatorcontrib><creatorcontrib>Abol-Enein, Hassan</creatorcontrib><creatorcontrib>Shokeir, Ahmed</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Current urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Delaimy, Wael K.</au><au>Awadalla, Amira</au><au>El-Assmy, Ahmed</au><au>Abol-Enein, Hassan</au><au>Shokeir, Ahmed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma</atitle><jtitle>Current urology</jtitle><date>2022-09-01</date><risdate>2022</risdate><volume>16</volume><issue>3</issue><spage>154</spage><epage>159</epage><pages>154-159</pages><issn>1661-7649</issn><eissn>1661-7657</eissn><abstract>BackgroundSquamous cell carcinoma (SCC) of the bladder is common in many regions around the world. Prognosis is very poor, as most cases are diagnosed at an advanced stage due to a lack of affordable and valid screening markers for this type of cancer. The diagnostic accuracy of urinary nuclear matrix protein-22 (NMP22), telomerase activity, and CD44 were evaluated in urine samples of patients with bladder SCC. Materials and methodsWe conducted a case-control study comprised of 60 consecutive newly diagnosed bladder SCC patients diagnosed by cystoscopy and histopathological examination, and controls were 60 outpatients with benign urologic conditions and healthy clinic visitors. Urine samples collected from each subject underwent testing for NMP22, telomerase activity, and CD44. Descriptive and correlational statistical analysis of cases and controls were carried out and receiver operating characteristic curve analysis was used to determine optimal cut-off points for the three assays. ResultsArea under the curve was calculated at 0.96, 0.93, and 0.62 for NMP22, telomerase, and CD44, respectively. Urine levels of NMP22 and telomerase activity were significantly higher in the SCC group compared to controls (p < 0.001). Urine CD44 levels were not significantly higher in the SCC group compared to controls (p = 0.111). The overall sensitivity of NMP22, telomerase, and CD44 was 96.7%, 87%, and 45%, respectively, while the specificity was 85%, 88.6%, and 86.7%, respectively. ConclusionsUrinary telomerase activity, followed by NMP22 urine levels, showed high diagnostic yield and could hold potential promise as urinary biomarkers for the diagnosis of bladder SCC.</abstract><pub>Lippincott Williams & Wilkins</pub><doi>10.1097/CU9.0000000000000098</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1661-7649 |
ispartof | Current urology, 2022-09, Vol.16 (3), p.154-159 |
issn | 1661-7649 1661-7657 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_eb269b0877134b5ea9d48329cf831ad1 |
source | Open Access: PubMed Central; HEAL-Link subscriptions: Lippincott Williams & Wilkins |
subjects | Special Topic: Advances in bladder cancer therapy: Original |
title | Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A29%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20urinary%20telomerase,%20CD44,%20and%20NMP22%20assays%20for%20detection%20of%20bladder%20squamous%20cell%20carcinoma&rft.jtitle=Current%20urology&rft.au=Al-Delaimy,%20Wael%20K.&rft.date=2022-09-01&rft.volume=16&rft.issue=3&rft.spage=154&rft.epage=159&rft.pages=154-159&rft.issn=1661-7649&rft.eissn=1661-7657&rft_id=info:doi/10.1097/CU9.0000000000000098&rft_dat=%3Cproquest_doaj_%3E2723156186%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c400t-5d2f1221575612d16653ffda0649c1d0509f2485ba156637648a89e4a46876d83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2723156186&rft_id=info:pmid/&rfr_iscdi=true |